Home LiteratureArticle Details
PMID: 18645038 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells.

Blood ·Vol. 112 ·No. 7 ·2008-10-01 ·Pages 2847-57

Hippen KL, Harker-Murray P, Porter SB, Merkel SC, Londer A, Taylor DK, Bina M, Panoskaltsis-Mortari A, Rubinstein P, Van Rooijen N, Golovina TN, Suhoski MM, Miller JS, Wagner JE, June CH, Riley JL, Blazar BR

Abstract

Previously, we showed that human umbilical cord blood (UCB) regulatory T cells (Tregs) could be expanded approximately 100-fold using anti-CD3/28 monoclonal antibody (mAb)-coated beads to provide T-cell receptor and costimulatory signals. Because Treg numbers from a single UCB unit are limited, we explored the use of cell-based artificial antigen-presenting cells (aAPCs) preloaded with anti-CD3/28 mAbs to achieve higher levels of Treg expansion. Compared with beads, aAPCs had similar expansion properties while significantly increasing transforming growth factor beta (TGF-beta) secretion and the potency of Treg suppressor function. aAPCs modified to coexpress OX40L or 4-1BBL expanded UCB Tregs to a significantly greater extent than bead- or nonmodified aAPC cultures, reaching mean expansion levels exceeding 1250-fold. Despite the high expansion and in contrast to studies using other Treg sources, neither OX40 nor 4-1BB signaling of UCB Tregs reduced in vitro suppression. UCB Tregs expanded with 4-1BBL expressing aAPCs had decreased levels of proapoptotic bim. UCB Tregs expanded with nonmodified or modified aAPCs versus beads resulted in higher survival associated with increased Treg persistence in a xeno-geneic graft-versus-host disease lethality model. These data offer a novel approach for UCB Treg expansion using aAPCs, including those coexpressing OX40L or 4-1BBL.

MeSH Terms
4-1BB Ligand/metabolism Animals Antigen-Presenting Cells/drug effects,immunology Apoptosis Regulatory Proteins/metabolism Bcl-2-Like Protein 11 Cell Proliferation/drug effects Cell Survival/drug effects Cells, Cultured Fetal Blood/cytology,drug effects Graft vs Host Disease/immunology Humans Membrane Proteins/metabolism Mice Microspheres Proto-Oncogene Proteins/metabolism Receptors, OX40/immunology Sirolimus/pharmacology Survival Analysis T-Lymphocytes, Regulatory/cytology,drug effects,immunology Tumor Necrosis Factor Receptor Superfamily, Member 9/immunology
Chemicals
4-1BB Ligand Apoptosis Regulatory Proteins BCL2L11 protein, human Bcl-2-Like Protein 11 Bcl2l11 protein, mouse Membrane Proteins Proto-Oncogene Proteins Receptors, OX40 Tumor Necrosis Factor Receptor Superfamily, Member 9 Sirolimus
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Hippen Keli L
University of Minnesota Cancer Center and Department of Pediatrics, Division of Bone, Blood and Marrow Transplantation, Minneapolis, USA. hippe002@umn.edu
Harker-Murray Paul
Porter Stephen B
Merkel Sarah C
Londer Aryel
Taylor Dawn K
Bina Megan
Panoskaltsis-Mortari Angela
Rubinstein Pablo
Van Rooijen Nico
Golovina Tatiana N
Suhoski Megan M
Miller Jeffrey S
Wagner John E
June Carl H
Riley James L
Blazar Bruce R
References (55)
55 references, click to expand
  1. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
    Cancer Gene Ther. 2006 Jun;13(6):555-62 PMID: 16410826
  2. Apoptosis by IL-2 deprivation in human CD8+ T cell blasts predominates over death receptor ligation, requires Bim expression and is associated with Mcl-1 loss.
    Mol Immunol. 2007 Feb;44(6):1446-53 PMID: 16806475
  3. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function.
    Blood. 2005 Jan 15;105(2):750-8 PMID: 15374887
  4. OX40 costimulation turns off Foxp3+ Tregs.
    Blood. 2007 Oct 1;110(7):2501-10 PMID: 17575071
  5. The Bcl-2 apoptotic switch in cancer development and therapy.
    Oncogene. 2007 Feb 26;26(9):1324-37 PMID: 17322918
  6. CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant tolerance.
    Transplantation. 2003 Nov 15;76(9):1375-9 PMID: 14627918
  7. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.
    Mol Ther. 2007 May;15(5):981-8 PMID: 17375070
  8. Immunobiology of allogeneic hematopoietic stem cell transplantation.
    Annu Rev Immunol. 2007;25:139-70 PMID: 17129175
  9. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.
    J Immunol. 1997 Dec 15;159(12):5921-30 PMID: 9550389
  10. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures.
    Blood. 2004 Jul 15;104(2):453-61 PMID: 15031211
  11. OX40 controls functionally different T cell subsets and their resistance to depletion therapy.
    J Immunol. 2007 Oct 15;179(8):5584-91 PMID: 17911646
  12. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease.
    Immunol Rev. 2006 Aug;212:8-27 PMID: 16903903
  13. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin.
    J Immunol. 2007 Jan 1;178(1):320-9 PMID: 17182569
  14. Clinical application of expanded CD4+25+ cells.
    Semin Immunol. 2006 Apr;18(2):78-88 PMID: 16458015
  15. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes.
    Clin Immunol. 2002 Dec;105(3):259-72 PMID: 12498807
  16. Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression.
    Scand J Immunol. 2007 Oct;66(4):435-40 PMID: 17850588
  17. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo.
    Blood. 2005 Dec 15;106(13):4131-8 PMID: 16118324
  18. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade.
    J Exp Med. 2001 Jun 4;193(11):1311-8 PMID: 11390438
  19. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells.
    Immunol Rev. 2006 Aug;212:60-73 PMID: 16903906
  20. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.
    Blood. 2005 Jun 15;105(12):4743-8 PMID: 15746082
  21. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo.
    Nat Immunol. 2002 Jan;3(1):33-41 PMID: 11740498
  22. Control of immune homeostasis by naturally arising regulatory CD4+ T cells.
    Curr Opin Immunol. 2003 Dec;15(6):690-6 PMID: 14630204
  23. Analysis of the underlying cellular mechanisms of anti-CD154-induced graft tolerance: the interplay of clonal anergy and immune regulation.
    J Immunol. 2005 Jul 15;175(2):771-9 PMID: 16002673
  24. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines.
    Hum Gene Ther. 1999 Aug 10;10(12):1983-91 PMID: 10466632
  25. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer.
    Expert Opin Biol Ther. 2007 Dec;7(12):1893-902 PMID: 18034654
  26. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells.
    Blood. 2004 Aug 1;104(3):895-903 PMID: 15090447
  27. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.
    J Exp Med. 2002 Aug 5;196(3):389-99 PMID: 12163567
  28. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance.
    Semin Immunol. 2004 Apr;16(2):81-8 PMID: 15036231
  29. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.
    Blood. 2005 Jul 1;106(1):376-83 PMID: 15755898
  30. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice.
    Blood. 2003 Oct 1;102(7):2522-31 PMID: 12791667
  31. Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease.
    Blood. 2007 Mar 1;109(5):2225-33 PMID: 17068147
  32. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.
    Nat Immunol. 2002 Feb;3(2):135-42 PMID: 11812990
  33. CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy.
    Blood. 2005 Nov 1;106(9):3068-73 PMID: 16020508
  34. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease.
    J Exp Med. 2002 Aug 5;196(3):401-6 PMID: 12163568
  35. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes.
    Nat Med. 2008 Jan;14(1):88-92 PMID: 18066074
  36. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
    J Immunol. 1995 Aug 1;155(3):1151-64 PMID: 7636184
  37. The NF-kappaB regulator Bcl-3 and the BH3-only proteins Bim and Puma control the death of activated T cells.
    Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10979-84 PMID: 16832056
  38. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans.
    Nat Rev Immunol. 2007 Aug;7(8):585-98 PMID: 17653126
  39. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients.
    J Immunol. 2006 Dec 15;177(12):8338-47 PMID: 17142730
  40. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Ann Surg Oncol. 2007 Feb;14(2):869-84 PMID: 17103257
  41. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
    Immunol Lett. 2005 Nov 15;101(2):210-6 PMID: 16026855
  42. CD4+CD25high regulatory cells in human peripheral blood.
    J Immunol. 2001 Aug 1;167(3):1245-53 PMID: 11466340
  43. Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'.
    Nat Med. 2000 Dec;6(12):1406-10 PMID: 11100129
  44. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.
    Blood. 2002 May 15;99(10):3493-9 PMID: 11986199
  45. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells.
    Blood. 2006 Feb 1;107(3):1018-23 PMID: 16210336
  46. OX40 ligand shuts down IL-10-producing regulatory T cells.
    Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13138-43 PMID: 16924108
  47. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.
    Nat Biotechnol. 2002 Feb;20(2):143-8 PMID: 11821859
  48. "In vivo" depletion of macrophages by liposome-mediated "suicide".
    Methods Enzymol. 2003;373:3-16 PMID: 14714393
  49. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells.
    Immunity. 2001 Sep;15(3):445-55 PMID: 11567634
  50. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.
    Blood. 2005 Apr 1;105(7):2845-51 PMID: 15591118
  51. TNF/TNFR family members in costimulation of T cell responses.
    Annu Rev Immunol. 2005;23:23-68 PMID: 15771565
  52. The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells.
    J Immunol. 2004 Aug 15;173(4):2428-34 PMID: 15294956
  53. Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via In utero or postnatal transfer.
    Blood. 1998 Nov 15;92(10):3949-59 PMID: 9808589
  54. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.
    Immunity. 2002 Feb;16(2):311-23 PMID: 11869690
  55. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.
    J Immunol. 2007 Dec 1;179(11):7295-304 PMID: 18025172
Article Info
Journal
Blood
Abbr.
Blood
ISSN
1528-0020
Published
2008-10-01
Epub
2008-00-21
Pages
2847-57
Language
English
Region
United States
NLM ID
7603509
PMCID
PMC2556620
Subset
IM
Grants
NCI NIH HHS · R01 CA105216 · United States
NCI NIH HHS · F32 CA067493 · United States
NHLBI NIH HHS · R37 HL56067 · United States
NCI NIH HHS · R01 CA105216-05 · United States
NIAID NIH HHS · P01 AI056299 · United States
NCI NIH HHS · P01 CA067493 · United States
NHLBI NIH HHS · R37 HL056067 · United States
NHLBI NIH HHS · R01 HL056067 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com